Crossject
3 News & Press Releases found

Crossject news

Anaphylactic shock is an absolute medical emergency. When anaphylactic shock is suspected, emergency services must be called and emergency first aid administered immediately. The only first-line treatment for anaphylactic shock is injectable adrenaline1.<

Apr. 19, 2020

Crossject and the US Department of Defense - DOD - (who is in charge of chemical, biological, radiological and nuclear defense – JPM CBRN Medical) have signed a cooperative research and development agreement for Zeneo® Midazolam.

« We are really happy to have signed this cooperative research and development agreement with the US Department of Defense (DOD), after their audit when they came to visit us in Dijon last July. We share a common interest by helping prote

Nov. 21, 2019

The American Food and Drug Administration (FDA) has granted Orphan Drug Designation to ZENEO® Midazolam for the treatment of status epilepticus (epileptic seizure lasting longer than 5 minutes).
The orphan designation for ZENEO® Midazolam improves Crossject’s international visibility and gives impetus to its current negotiations for partnerships with pharmaceutical laboratories. 

Feb. 20, 2018